Eledon Pharma Files 2025 Proxy Statement
Ticker: ELDN · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1404281
| Field | Detail |
|---|---|
| Company | Eledon Pharmaceuticals, Inc. (ELDN) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
Eledon Pharma's 2025 proxy statement is out, detailing exec pay & stock awards for 2022-2024.
AI Summary
Eledon Pharmaceuticals, Inc. filed a DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2025. The filing details executive compensation and equity awards for the years 2022, 2023, and 2024. It also notes the company's former names, Novus Therapeutics, Inc. and Tokai Pharmaceuticals Inc.
Why It Matters
This filing provides crucial information about how Eledon Pharmaceuticals compensates its top executives and grants them equity, which can impact shareholder value and company strategy.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the details within can reveal insights into executive compensation and potential future stock dilution.
Key Numbers
- 2022-2024 — Equity Award Years (Covers executive equity awards granted and valued over these fiscal years.)
- 20250429 — Filing Date (Date the DEF 14A was officially submitted to the SEC.)
Key Players & Entities
- Eledon Pharmaceuticals, Inc. (company) — Filer
- Novus Therapeutics, Inc. (company) — Former Company Name
- Tokai Pharmaceuticals Inc (company) — Former Company Name
- 20250429 (date) — Filing Date
- 20250610 (date) — Period of Report
- 1231 (date) — Fiscal Year End
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information regarding the company's annual meeting, including details on executive compensation, director nominations, and other corporate governance matters.
What specific periods do the executive compensation and equity award details cover?
The filing references executive compensation and equity award data for the fiscal years 2022, 2023, and 2024.
Has Eledon Pharmaceuticals, Inc. operated under any previous names?
Yes, the company was formerly known as Novus Therapeutics, Inc. (name change effective May 11, 2017) and prior to that, Tokai Pharmaceuticals Inc (name change effective June 22, 2007).
When is Eledon Pharmaceuticals' fiscal year end?
Eledon Pharmaceuticals' fiscal year ends on December 31st.
What is the filing date of this DEF 14A?
This DEF 14A filing was made on April 29, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Eledon Pharmaceuticals, Inc. (ELDN).